Tenarad

Tenarad is a radioimmunotherapeutic agent developed by Philogen, consisting of the human monoclonal antibody fragment F16 in a Small Immunoprotein (SIP) format, radiolabeled with the isotope Iodine-131 (131I). The F16 antibody specifically targets the A1 domain of Tenascin-C, an extracellular matrix protein that is highly overexpressed in the stroma of various solid tumors and in the bone marrow of patients with hematological malignancies, such as acute myeloid leukemia (AML), while remaining virtually absent in most healthy adult tissues. By binding to Tenascin-C, Tenarad facilitates the targeted delivery of beta-emitting radiation directly to the tumor microenvironment, leading to localized cytotoxic effects through DNA damage. It has been investigated in clinical trials for the treatment of refractory solid tumors, including head and neck cancer and lung cancer, as well as in combination regimens for leukemia.

Brand names

Tenarad

Other names

Iodine (131I) F16SIP